An interventional study of High Hyaluronic Acid concentrations (0.5 mg/ml) and Low Hyaluronic Acid concentrations (0.125 mg/ml) in Infertility, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.
Among the 139 studies in Infertility with a site in China, this one is the 20th largest by planned enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2024, is one of 65 with no phase, reaches primary completion later than 8 of the 40 other live ones, and was the 112th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 20–40 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 36–39 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Sites in China
Ages 20–40 · Women only
Tang-Du Hospital · Sites in China
Ages 20–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 15 · Phase 4 14
First in 2003; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 858 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 248 across the 107 interventional studies, 550 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 139 have an industry lead sponsor. The 10 most frequent:
Northwest Women's and Children's Hospital, Xi'an, Shaanxi is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Northwest Women's and Children's Hospital, Xi'an, Shaanxi has 3 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
12 of the studies in Infertility with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
| NCT07050537The First Affiliated Hospital with Nanjing Medical UniversityA Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology | 2027-03-31 |
| NCT07533630Reproductive & Genetic Hospital of CITIC-XiangyaProspective International Multi-center Clinical Trial of PGT-A Upgrade | 2027-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 139 studies in Infertility with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the live birth rates of high concentration of Hyaluronic Acid (0.5 mg/ml) transfer medium (EmbryoGlue®) to those containing low Hyaluronic Acid concentrations (0.125 mg/ml) (G2 medium) in women undergoing single fresh and frozen blastocyst transfer.
The single blastocyst-stage embryo transfer cycles will be randomised in a 1:1 allocation, with block sizes of 2 and 4 on the day of Embryo Transfer (ET). This randomisation process will be centrally managed via a web-based electronic data capture system and will be stratified according to the treatment center. The allocation sequence and the designated treatment will be completely concealed from the participating couples, clinicians - including those conducting the transfer procedures - and outcome assessors. Given the intrinsic viscous nature of EmbryoGlue, embryologists, who who are responsible for the procedures in the laboratory will not be subjected to blinding. Only at the end of the study, when data collection is completed, the allocation sequence will be revealed to the primary investigators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High HA concentrations (0.5 mg/ml)
Biological: High Hyaluronic Acid concentrations (0.5 mg/ml)
Low HA concentrations (0.125 mg/ml)
Biological: Low Hyaluronic Acid concentrations (0.125 mg/ml)
Hyaluronic Acid(EmbryoGlue®)
Hyaluronic Acid (G2 medium)
Live birth rate
The primary outcome was Live birth rate per embryo transfer.
Time frame: Live birth is defined as the birth of at least one live baby after 24 weeks of gestation.
Biochemical pregnancy
Biochemical pregnancy is defined as serum beta-human chorionic gonadotropin β-hCG \> 20 IU/L 12 days after embryo transfer.
Time frame: 12 days after embryo transfer.
Clinical pregnancy
Clinical pregnancy is defined as the presence of at least one gestational sac confirmed by ultrasonography (ectopic pregnancy is included as a clinical pregnancy).
Time frame: 6-8 weeks after embryo transfer
Ongoing pregnancy
Ongoing pregnancy is defined as the presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.
Time frame: after 12 weeks of gestation.
Miscarriage
Miscarriage is defined as spontaneous loss of an intrauterine pregnancy before 20 completed weeks of gestation.
Time frame: 20 weeks of gestation.
Ectopic pregnancy
Ectopic pregnancy is defined as a pregnancy implanted outside the uterine cavity, diagnosed by ultrasonography, surgical visualization, or histopathology.
Time frame: After 4 to 6 weeks of embryo transfer
Multiple pregnancy
Multiple pregnancy is defined as a pregnancy with two or more gestational sacs or fetal heartbeats at 7 weeks of gestation.
Time frame: 7 weeks of gestation.
hypertensive disorders in pregnancy
Comprising essential hypertension; pregnancy induced hypertension; pre-eclampsia and eclampsia.
Time frame: From 20 weeks of gestation up to at birth
Placental implantation disorders
Placental implantation disorders encompass placenta previa, placenta accreta spectrum, placental abruption and/or abnormal cord insertion
Time frame: From 20 weeks of gestation up to at birth
Preterm birth
Delivery of a fetus at less than 37 and more than 28 weeks gestational age
Time frame: At birth
Preterm premature rupture of membranes
Preterm premature rupture of membranes is defined as the leakage of amniotic fluid through the cervical os before 37 weeks of gestation and before the onset of labor
Time frame: Before 37 weeks of gestation and before the onset of labor
Mode of delivery
Vaginal delivery or cesarean delivery
Time frame: At birth
Gestational age
Gestational age recorded at delivery
Time frame: At birth
Birth weight
Weight of baby born (grams)
Time frame: At birth
low birth weight
Weight of baby born \< 2500 g
Time frame: At birth
Very low birth weight
Weight of baby born \< 1500 g
Time frame: At birth
Mean birth weight
By checking medical records
Time frame: 1 year after embryo transfer
Macrosomia
Weight of baby born \> 4000 g
Time frame: At birth
Large for gestational age
Birthweight \> 90th percentile
Time frame: At birth
Small for gestational age
Birthweight \< 10th percentile
Time frame: At birth
Neonatal intensive care unit admission
Safety outcome. Number of pregnancies for which newborn is admitted to the NICU
Time frame: Birth up to 1 year
Stillbirth or late fetal death
Fetal death at 20 or more weeks' gestation
Time frame: At birth
Early neonatal death
Time frame: Up to 28 days after birth
Congenital anomaly or birth defect
Any congenital anomalies detected in baby born
Time frame: Birth to first year of life
Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 15 months is below that.
Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwest Women's and Children's Hospital, Xi'an, Shaanxi